X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

Key Points

• Quarterly results: X4 reported an adjusted EPS loss of ($0.16), beating the consensus ($0.20) by $0.04, but revenue missed at $2.71M versus $3.20M, and the company remains deeply unprofitable with a net margin of -225.55% and ROE of -115.27%.
• Market reaction and outlook: Shares rose about 4.4% to $4.39 on the news, while Wall Street consensus is a "Hold" with a $8.50 price target and broker views range from Guggenheim's "Buy" ($12 PT) to mixed sell/hold notes.
• Balance sheet and ownership: X4 shows strong liquidity (quick ratio 9.98, current ratio 10.16), modest leverage (debt/equity 0.41), and roughly 72% institutional ownership, including a recent large $13.48M stake by Braidwell LP.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04, FiscalAI reports. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The company had revenue of $2.71 million for the quarter, compared to analyst estimates of $3.20 million.

X4 Pharmaceuticals Stock Up 4.4%

Shares of XFOR traded up $0.19 during mid-day trading on Wednesday, hitting $4.39. 500,104 shares of the company's stock were exchanged, compared to its average volume of 453,509. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The firm has a fifty day moving average of $3.99 and a two-hundred day moving average of $3.80. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. The stock has a market cap of $398.68 million, a price-to-earnings ratio of -1.01 and a beta of 0.31.

Wall Street Analyst Weigh In

Several brokerages have recently commented on XFOR. Weiss Ratings upgraded shares of X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Guggenheim began coverage on shares of X4 Pharmaceuticals in a research note on Monday, March 9th. They set a "buy" rating and a $12.00 price target on the stock. Finally, Wall Street Zen upgraded shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, March 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $8.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at $90,000. Susquehanna Portfolio Strategies LLC acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at $173,000. Man Group plc acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at $97,000. Balyasny Asset Management L.P. acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at $258,000. Finally, Braidwell LP acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at $13,476,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.